Pingwei Powder Veterinary Grade API is a single-entity active pharmaceutical ingredient powder released for further processing into veterinary tablets, injections, capsules, powders, granules, premixes, and solutions. The material is non-sterile as supplied and is not formulated for direct administration. The model designation is Pingwei Powder Veterinary Grade API; no sterile, micronized, or lyophilized sub-grades are covered by this document. Each batch is accompanied by a certificate of analysis that lists batch-specific results for assay, related substances, water content, residue on ignition, elemental impurities, residual solvents, particle size distribution, bulk density, tapped density, and microbial enumeration. Where a pharmacopoeial monograph exists, the release specification follows the monograph with additional controls where required. Where no monograph exists, the specification is established under the applicant’s pharmaceutical quality system and approved by the relevant regulatory authority. For parenteral dosage forms, the finished product must comply with sterility and bacterial endotoxin requirements such as USP <71> and USP <85>; compliance with these tests is the responsibility of the finished product manufacturer.

Material Characterization and Pharmacopoeial Alignment

Batch release begins with identification by infrared absorption and liquid chromatographic assay. The assay method is stability-indicating and validated for specificity, linearity, accuracy, precision, range, and robustness under ICH Q2(R1) or VICH GL2. Related substances are reported with identification and qualification thresholds derived from ICH Q3A; the usual reporting threshold is 0.05%, the identification threshold is 0.10%, and the qualification threshold is 0.15% for APIs produced under a well-controlled route. Where an established veterinary pharmacopoeial monograph imposes different limits, the monograph limits take precedence.

Water content is determined by USP <921> Method Ia. For non-hygroscopic APIs, a release limit of not more than 0.5% (w/w) is common because free water affects solid-state stability, flow, and microbial growth; the exact limit is stated on the certificate of analysis. Residue on ignition is measured by USP <281> with a typical release criterion of not more than 0.1% (w/w). Elemental impurities are controlled by USP <232>/<233> using the route-specific permitted daily exposure limits of ICH Q3D. Residual solvents are tested by headspace gas chromatography under USP <467> with limits assigned according to VICH GL18.

Particle size distribution is assessed by laser diffraction using ISO 13320:2020; the certificate of analysis reports D10, D50, and D90. Bulk and tapped densities are determined by USP <616> and used to calculate the Hausner ratio and Carr index. Powder flow is further characterized by shear cell testing using ASTM D6773 for critical dry blends. FTIR identity testing requires a reference standard and is performed on the received powder without preparation. If the API is hygroscopic, sample handling is performed under dry nitrogen to prevent spectral interference from adsorbed water. The powder is not classified as sterile, and microbial quality is controlled by USP <61> and <62> with absence of Salmonella where applicable and absence of Escherichia coli where the production environment requires enteric pathogen control.

In low-dose tablet and capsule manufacturing, blend uniformity is the primary process risk. The API is screened through a 500 µm stainless-steel hand screen and pre-blended with a compatible diluent in a diffusion mixer or high-shear mixer. The pre-blend should represent not less than 10% of the final blend weight to minimize segregation. Blend samples are withdrawn from 10 to 20 locations and assayed; a relative standard deviation of not more than 5.0% is the usual acceptance criterion before compression. Finished tablet content uniformity is evaluated by USP <905>. When the Hausner ratio exceeds 1.25 or the Carr index exceeds 25%, direct compression is not recommended. Instead, the material is granulated using dry roller compaction or wet granulation. Dry granulation by roller compaction at 20–40 kN roll force and milling through a 1.0 mm screen improves flow and reduces capping; ribbon density of 1.0–1.2 g/cm³ is a typical starting target. Wet granulation with aqueous or hydroalcoholic binder can improve content uniformity but may increase degradation risk if the API is moisture-sensitive. Capsule filling on an automatic dosator or tamping-pin machine requires free-flowing granules with a tapped density above 0.50 g/cm³ where low-dose filling is used; these values are operational starting points and must be confirmed during development. The lubricant concentration is limited to 0.5–1.0% w/w magnesium stearate to avoid delayed dissolution caused by hydrophobic lubricant films. Tablet friability is controlled to not more than 1.0% using USP <1216>, and dissolution is monitored by USP <711>.

Dissolution performance may be impaired if the API particles are too large or if the blend is over-lubricated. Particle size reduction by air-jet milling can be used for poorly soluble APIs to increase surface area in accordance with the Noyes–Whitney equation; however, particles below 10 µm often exhibit electrostatic charging and agglomeration. In such cases, the milled material is mixed with a hydrophilic carrier or granulated immediately after milling.

What Differences Exist Between Pingwei Powder and Feed-Grade or Technical-Grade Powders?

The primary difference is regulatory control. Unlike feed-grade or technical-grade powders, the veterinary API grade is released under a pharmaceutical quality system with defined identity, assay, impurity, and microbial specifications. Feed-grade powders may be supplied against non-specific titration methods or without a reported purity assignment; technical-grade powders are not manufactured under ICH Q7 for pharmaceutical quality systems. These differences affect formulation and safety. When Pingwei Powder is used to replace a feed-grade source in a premix, the higher assay and controlled impurity profile require recalculation of the carrier addition rate to maintain the same final drug concentration. Failure to recalculate can produce excessive drug carryover or underdosing. For parenteral or solution applications, feed-grade or technical-grade material should not be substituted because of the absence of endotoxin and particulate controls.

For injection and solution compounding, the powder is dissolved in Water for Injection under controlled pH and temperature. The dissolution vessel should be stainless steel or glass-lined to avoid metal ion contamination. The batch solution is passed through a 0.45 µm prefilter and then a 0.22 µm sterilizing-grade filter; filter compatibility is confirmed with PVDF, PES, or nylon membranes under worst-case conditions. The solution is not sterile before filtration, and the API as supplied does not meet sterile API requirements. Endotoxin control is applied at the finished product stage because the API may be distributed in non-sterile drums. Formulation development should include forced degradation studies under VICH GL3 or ICH Q1A to define pH and temperature limits. The pH of the finished solution is adjusted with dilute hydrochloric acid or sodium hydroxide only after the API has dissolved. Where aqueous solubility is insufficient, co-solvents such as propylene glycol, glycerin, or polyethylene glycol 400 are used; the effect of co-solvent on crystallization and precipitation must be evaluated. Solutions for injection are finished by terminal sterilization or aseptic filling, with sterility testing by USP <71> and bacterial endotoxin testing by USP <85>. The limit for bacterial endotoxins is route-specific and derived from the maximum dose; no universal endotoxin limit is assigned to the API. Insoluble particulate matter in the finished injection is controlled by USP <788>.

Stability of the compounded solution should be supported by photostability data; if the API contains a chromophore, exposure to light may generate free radicals. The solution should be filled under nitrogen or argon if oxygen-sensitive; dissolved oxygen is reduced by sparging with nitrogen to below 1.0 mg/L before filling. These measures are particularly relevant for injections packaged in clear glass vials.

When Pingwei Powder Replaces Feed-Grade API in Premix and Medicated Feed Applications

In premix manufacture, the powder is dispersed into a carrier such as lactose monohydrate, rice hulls, or corncob in a ribbon or paddle mixer. The carrier should have a particle size within 2 times the API D50 to reduce segregation. The API is pre-blended with a portion of carrier at a 1:10 ratio before addition to the full bulk. Mixing time is determined by sampling at 5-minute intervals and assaying for drug content; the target relative standard deviation for medicated feed homogeneity is typically not more than 5.0% in process validation. Scale-up from pilot to production requires re-qualification of blend times because powder flow and segregation differ with vessel size. Segregation is assessed by sampling at discharge points; acceptable variation in assay should not exceed 5.0% RSD across the batch.

In powder and granule dosage forms, the API is blended with fillers, binders, and flavoring agents before sachet filling or reconstitution. Because the powder may be moisture-sensitive, the relative humidity in the processing suite is controlled below 60% RH where the water activity of the blend is critical; the exact limit is established in the stability protocol. Packaging should protect from light and moisture; the standard pack is 25 kg HDPE drum with double LDPE liners. Storage is at controlled room temperature unless otherwise stated on the certificate of analysis. Incompatibility with strong oxidizing agents or strong acids and bases should be evaluated; the API should not be dry-blended with amine-based excipients if such excipients are known to cause adduct formation or discoloration for the specific active moiety. Published data for Pingwei Powder in these chemically challenging matrices is limited.